Concepedia

Publication | Open Access

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

DOIFull Paper Access

11

Citations

17

References

2022

Year

Javier Trujillo‐Santos, Dominique Farge, José María Pedrajas, Covadonga Gómez‐Cuervo, Aitor Ballaz, Andrei Braester, Isabelle Mahé, Aurora Villalobos, José Antonio Porras, Manuel Monréal,
Research and Practice in Thrombosis and Haemostasis

Abstract

In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.

References

YearCitations

Page 1